Abstract
The problem of the advantage of using nortriptyline (NT) plasma level during treatment for endogenous depression has been approached. In an ordinary psychiatric department, 34 patients had their NT level checked the second week of treatment and their dosage subsequently adjusted, if it was outside the recommended therapeutic plasma range (50–150 ng/ml). A cautious dose policy led to low plasma levels followed by dose increase in about 40% of the patients. Only in a few patients was the plasma level above the upper limit. The general outcome, about 20% failures, was compatible with the best in literature. These and other results suggest that controlling the NT plasma concentration, aiming at a level of around 100 ng/ml, might offer a therapeutic advantage, but only if the department has established a therapeutic strategy that involves such a monitoring system. The therapeutic outcome was the same as or even better in the old-age group than that in patients under 65 years of age.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alexandersson, B., Åsberg, M., Tuck, D.: Relationship between the steady-state plasma concentration of nortriptyline and some of its pharmacological effects. In: Biological effects of drugs in relation to their plasma concentrations, Davids and Prichard, eds., pp. 191–199. London: Macmillan 1973
Åsberg, M.: Treatment of depression with tricyclic drugs—pharmacokinetic and pharmacodynamic aspects. Pharmakol.-Psychiatry 9, 18–26 (1976)
Åsberg, M., Cronholm, B., Sjöqvist, F., Tuck, D.: Relationship between plasma levels and therapeutic effect of nortriptyline. Br. Med. J. 1971 III, 331–334
Åsberg, M., Kragh-Sørensen, P., Mindham, R. H. S., Tuck, J. R.: International reliability and communicability of a rating scale for depression. Psychol. Med. 3, 458–465 (1973)
Kragh-Sørensen, P., Hansen, C. E., Larsen, N.-E., Naestoft, J., Hvidberg, E. F.: Long-term treatment of endogenous depression with nortriptyline with control of plasma levels. Psychol. Med. 4, 174–180 (1974)
Kragh-Sørensen, P., Hansen, C. E., Åsberg, M.: Plasmanortriptyline levels in endogenous depression. Lancet 1973 I, 113–115
Kragh-Sørensen, P., Hvidberg, E. F., Hansen, C. E., Baastrup, P. C.: Therapeutic control of plasma concentrations and long-term effect of nortriptyline in recurrent affective disorders. Pharmakol. Psychiatry 9, 178–182 (1976a)
Kragh-Sørensen, P., Hansen, C. E., Baastrup, P. C., Hvidberg, E. F.: Self-inhibiting action of nortriptyline's antidepressive effect at high plasma levels. Psychopharmacologia (Berl.) 45, 305–312 (1976b)
Montgomery, S. A., Braithwaite, R. A., Crammer, J. L.: Routine nortriptyline levels in treatment of depression. Br. Med. J. 1977II, 166–167
Morris, J. B., Beck, A. T.: The efficacy of antidepressant drugs. Arch. Gen. Psychiatry 30, 667–674 (1974)
Nies, A., Robinson, D. S., Friedman, M. J., Green, R., Cooper, T. B., Ravaris, C. L., Ives, J. O.: Relationship between age and tricyclic antidepressant plasma levels. Am. J. Psychiatry 134, 790–793 (1977)
Sjöqvist, F.: A pharmacokinetic approach to the treatment of depression. Int. Pharmacopsychiatry 6, 147–169 (1971)
Ziegler, V. E., Clayton, P. J., Biggs, J. T.: A comparison study of amtriptyline and nortriptyline with plasma levels. Arch. Gen. Psychiatry 34, 607–612 (1977)
Ziegler, V. E., Clayton, P. J., Taylor, J. R., Co, B. T., Biggs, J. T.: Nortriptyline plasma levels and therapeutic response. Clin. Pharmacol. Ther. 20, 458–463 (1976)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sørensen, B., Kragh-Sørensen, P., Larsen, NE. et al. The practical significance of nortriptyline plasma control. Psychopharmacology 59, 35–39 (1978). https://doi.org/10.1007/BF00428027
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00428027